Articles by Rob Dillard
Dr. Marisa Bittoni discusses the possible link between vaping and lung cancer risk.
Arun Krishna, of AstraZeneca, talks about the phase 3 FLAURA2 trial, which assessed Tagrisso in patients with NSCLC.
Bronchoalveolar lavage supernatant may serve as a possible target in early-stage lung cancer research, a recent study showed.
Immune checkpoint inhibitor therapy alone may be recommended for older adults with previously untreated advanced NSCLC.
Prevention measures should be taken to protect workers who are exposed to RCS from lung cancer risk.
A combination of targeted therapy and immunotherapy may benefit patients with non-small cell lung cancer.
Accurately diagnosing pneumonitis in patients with inoperable stage III non-small cell lung cancer is challenging.
Analyzing the exhaled breath of patients with mesothelioma shows tremendous potential as a screening tool.
A novel technology based on nanosensors may be able to effectively detect early-stage lung tumors.
Iovance Biotherapeutics has announced a clinical program update for LN-145 TIL therapy in the treatment of NSCLC.
Alexandra Potter talks about health disparities that exist in lung cancer screening and treatment, and possible solutions.
Tai chi improves sleep quality, as well as physical and psychological outcomes, in patients with advanced lung cancer.
Over 50% of patients with advanced non-small cell lung cancer are untested for biomarkers.
Structural racism plays a fundamental role in the unequal distribution of lung cancer risk factors.
Dr. Mona S. Jhaveri discusses the importance of Lung Cancer Awareness Month, recent breakthroughs in lung cancer, and more.
Mark McDonough, CEO of ChromaCode, discusses an innovative, high-definition PCR assay for enhanced detection of NSCLC.
Asbestos exposure led to a higher incidence of asbestos-related lung cancers in naval personnel.
Dr. Melissa Johnson, of Sarah Cannon, discusses lung cancer trials to keep an eye on and unmet needs in lung cancer.
Taxus chinensis has significant therapeutic potential in alleviating non-small cell lung cancer.
BAP1 immunohistochemistry and p16 (CDKN2A) deletion contribute to providing a definitive diagnosis of mesothelioma.
630 Madison Ave.
Manalapan, NJ 07726
Connect
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.